GLP-1 agonists with double actions, or the combination of drugs with different targets, like liraglutide and elafibranor [135], are therefore an interesting field to explore and exploit for NAFL/NASH treatment. The gene discussed is GCG; the disease is non-alcoholic fatty liver.